Joseph Paul, MD
Infectious Disease · Brooklyn, NYNPI 1558387431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,325 of the $186,187 with a category attached, or 70.5%. 15 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 47.2% of the total. Reporting peaked in 2019 at $90,605 and has fallen 87.0% since, to $11,757 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $389.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$88K
- Gilead$55K
- Viiv Healthcare Company$34K
- Janssen Products, LP$7K
- Johnson & Johnson$2K
- Theratechnologies Inc.$564
- plus $886 from 9 others
What the payments were for
- Consulting fees$31,05017%
- Speaking & faculty fees$131,32571%
- Travel & lodging$12,9557%
- Food & beverage$10,7586%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 111 | $87,914 |
| Gilead | 123 | $54,743 |
| Viiv Healthcare Company | 139 | $33,642 |
| Janssen Products, LP | 8 | $6,583 |
| Johnson & Johnson | 63 | $1,856 |
| Theratechnologies Inc. | 6 | $564 |
| AbbVie | 16 | $502 |
| Alkermes, Inc. | 1 | $125 |
| Novo Nordisk | 3 | $69 |
| Lilly USA, LLC | 2 | $46 |
| Pfizer | 2 | $41 |
| Merck | 1 | $32 |
| GSK | 1 | $29 |
| Global Blood Therapeutics, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,187 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 604 | $2,416,332 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 269 | $1,229,817 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 266 | $1,073,253 |
| JulucaDolutegravir/Rilpivirine | 128 | $450,781 |
| TivicayDolutegravir Sodium | 197 | $443,564 |
| DovatoDolutegravir Sodium/Lamivudine | 137 | $393,114 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 75 | $336,175 |
| CabenuvaCabotegravir/Rilpivirine | 32 | $224,271 |
| PrezcobixDarunavir/Cobicistat | 82 | $210,292 |
| DescovyEmtricitabine/Tenofov Alafenam | 67 | $146,876 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 41 | $139,825 |
| JanuviaSitagliptin Phosphate | 98 | $67,476 |
| JardianceEmpagliflozin | 81 | $53,945 |
| Diclofenac Sodium | 32 | $30,931 |
| OzempicSemaglutide | 32 | $29,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $54,743 | $2,899,382746 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Tivicay, Dovato, Cabenuva | $33,642 | $2,584,983760 claims |
| Janssen Products, LPSymtuza | $6,583 | $1,229,817269 claims |
| Johnson & JohnsonPrezcobix | $1,856 | $210,29282 claims |
| MerckJanuvia, Janumet | $32 | $76,871110 claims |
| Novo NordiskOzempic, Rybelsus | $69 | $59,10254 claims |
| PfizerEliquis | $41 | $23,45934 claims |
| GSKIncruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $29 | $22,18874 claims |
| Lilly USA, LLCTrulicity | $46 | $13,72411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 799 infectious disease providers in New York.
Other infectious disease in Brooklyn
- Andre BrutusBrooklyn$303K
- Marcus SandlingBrooklyn$157K
- Alan SteinBrooklyn$90K
- Jessica YagerBrooklyn$70K
- Yusuf AfacanBrooklyn$19K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.